The market taxonomy by type classifies rapid test services into five technology families that together constitute the full market size. Immunoassay kits, including ELISA and chemiluminescent formats, capture roughly 30 % of revenue, owing to their broad target range and established laboratory workflows. Molecular PCR kits contribute about 28 %, as nucleic‑acid amplification delivers species‑level pathogen identification critical for seed certification and disease outbreak tracing. Biosensor platforms—electrochemical, optical, or nanomaterial‑based—represent 22 % of the market, reflecting growing adoption of real‑time, on‑field analytics that reduce sample‑to‑decision time. Lateral flow devices hold a 15 % share, favored for their simplicity, low cost, and suitability for low‑resource environments. Finally, microfluidic cartridge systems account for the remaining 5 %, offering integrated sample preparation and multiplexing but remaining price‑sensitive. The proportional contribution of each type is shaped by factors such as assay sensitivity, regulatory acceptance, and end‑user infrastructure, thereby determining overall market valuation. Emerging hybrid platforms that combine immuno‑capture with electrochemical readout are beginning to capture market attention, potentially reshaping the current distribution as they achieve higher throughput at comparable costs.